Expert Opinion on Orphan Drugs

Papers
(The H4-Index of Expert Opinion on Orphan Drugs is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Risdiplam as an orphan drug treatment of spinal muscular atrophy in adults and children (2 months or older)14
Quality of life of patients with acromegaly: comparison of different therapeutic modalities12
Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? a systematic scoping review11
Molecular aspects of the altered Angiotensin II signaling in Gitelman’s syndrome10
Management of pulmonary hypertension in infants8
Elucidating the pathogenesis of adenosine deaminase 2 deficiency: current status and unmet needs7
Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact6
Overview of genetic testing in Prader-Willi syndrome6
0.043358087539673